Amylyx Pharmaceuticals, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Joshua Cohen and Justin Klee; Other NEO average total compensation $1.47M.
- 2024-12-31: PEO Joshua Cohen and Justin Klee; Other NEO average total compensation $2.42M.
- 2023-12-31: PEO Joshua Cohen and Justin Klee; Other NEO average total compensation $3.09M.
- 2024-12-31: PEO Joshua Cohen and Justin Klee; Other NEO average total compensation $2.42M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Joshua Cohen and Justin Klee | $1.47M | $5.03M | $67.00 | -$144.74M | 2026-04-23 | ||||
| 2024-12-31 | Joshua Cohen and Justin Klee | $2.42M | $152.16K | $21.00 | -$301.74M | 2026-04-23 | ||||
| 2023-12-31 | Joshua Cohen and Justin Klee | $3.09M | -$3.22M | $81.00 | $49.27M | 2026-04-23 | ||||
| 2024-12-31 | Joshua Cohen and Justin Klee | $2.42M | $152.16K | $21000.00 | -$301.74M | 2025-04-24 | ||||
| 2023-12-31 | Joshua Cohen and Justin Klee | $3.09M | -$3.22M | $81000.00 | $49.27M | 2025-04-24 | ||||
| 2022-12-31 | Joshua Cohen and Justin Klee | $4.26M | $10.18M | $204000.00 | -$198.38M | 2025-04-24 | ||||
| 2023-12-31 | Joshua Cohen and Justin Klee | $3.09M | -$3.22M | $49.27K | Product revenue, net $380.79 | 2024-04-24 | ||||
| 2022-12-31 | Joshua Cohen and Justin Klee | $4.26M | $10.18M | -$198.38M | $22.23 | 2024-04-24 | ||||
| 2021-12-31 | Joshua Cohen and Justin Klee | $2.06M | $3.03M | -$87.93M | 2024-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |